Navigation Links
Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
Date:4/7/2008

Results Reported at American Association for Dental Research Meeting

DURHAM, N.C., April 7, 2008 /PRNewswire/ -- Parion Sciences, Inc., a privately-held, development-stage pharmaceutical company dedicated to treating diseases resulting from the failure of the body's mucosal defenses, today announced preliminary results from a Phase I clinical safety study of a novel sodium channel blocker, P-552-02, as a topical therapy for dry mouth associated with primary Sjogren's syndrome. The preliminary results of the study showed that P-552-02 was safe and well tolerated, both locally in the oral cavity and systemically. No side effects or other safety issues were reported in the study. The results were reported on April 4 by Athena Papas, DMD, Ph.D., Professor at Tufts University School of Dental Medicine at the Annual Meeting of the American Association for Dental Research.

The trial was a 28-day, 30-patient, randomized, double-blind, placebo- controlled, crossover study designed to assess the effect of a six-time daily oral rinse formulation of P-552-02 versus placebo on oral and systemic safety parameters and the symptoms of dry mouth. The primary efficacy endpoint, a global improvement in the "feeling of dry mouth" as determined by a single retrospective "recall" report at day 28, was not met. However, an assessment of "global change in dry mouth" as determined by the change in visual analog scale (VAS) measurements 12 hours after dosing at day 7 and day 28 revealed significant improvement in the global dry mouth scores. VAS scores that measured the change at day 28 in mouth dryness, tongue dryness and ability to sleep also indicated that subjects improved on P-552-02 compared to placebo. The work was funded by Parion Sciences under a clinical study agreement with Tufts University.

"We are very encouraged with the outcome of this study. The improvements seen in this safety study, with the low dose and small sample size, demonstrate the potenti
'/>"/>

SOURCE Parion Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
5. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
6. Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
7. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
8. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
9. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
10. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
11. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Inc. (NASDAQ: HOLX ) announced today the Company,s ... 27, 2015.  Quarterly revenues of $693.9 million increased 9.7% ... currency basis.  GAAP earnings per share (EPS) of $0.10 ... "Our third quarter financial results demonstrate the ... that can grow sustainably on both the top and ...
(Date:7/29/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology and medical device industries, with operations ... the United States , today announced that it ... after the New York Stock Exchange closes on Thursday, ... 14, 2015 Shanghai time). The earnings release will be ...
(Date:7/29/2015)... SAN DIEGO, July 29, 2015 Neurocrine Biosciences, Inc. (NASDAQ: ... ended June 30, 2015. For the second quarter of 2015, the ... per share, compared to a net loss of $13.4 million, or ... the six months ended June 30, 2015, the Company reported a ... compared to net loss of $25.2 million, or $0.35 loss per ...
Breaking Medicine Technology:Hologic Announces Financial Results for Third Quarter of Fiscal 2015 2Hologic Announces Financial Results for Third Quarter of Fiscal 2015 3Hologic Announces Financial Results for Third Quarter of Fiscal 2015 4Hologic Announces Financial Results for Third Quarter of Fiscal 2015 5Hologic Announces Financial Results for Third Quarter of Fiscal 2015 6Hologic Announces Financial Results for Third Quarter of Fiscal 2015 7Hologic Announces Financial Results for Third Quarter of Fiscal 2015 8Hologic Announces Financial Results for Third Quarter of Fiscal 2015 9Hologic Announces Financial Results for Third Quarter of Fiscal 2015 10Hologic Announces Financial Results for Third Quarter of Fiscal 2015 11Hologic Announces Financial Results for Third Quarter of Fiscal 2015 12Hologic Announces Financial Results for Third Quarter of Fiscal 2015 13Hologic Announces Financial Results for Third Quarter of Fiscal 2015 14Hologic Announces Financial Results for Third Quarter of Fiscal 2015 15Hologic Announces Financial Results for Third Quarter of Fiscal 2015 16Hologic Announces Financial Results for Third Quarter of Fiscal 2015 17Hologic Announces Financial Results for Third Quarter of Fiscal 2015 18Hologic Announces Financial Results for Third Quarter of Fiscal 2015 19Hologic Announces Financial Results for Third Quarter of Fiscal 2015 20Hologic Announces Financial Results for Third Quarter of Fiscal 2015 21Hologic Announces Financial Results for Third Quarter of Fiscal 2015 22Hologic Announces Financial Results for Third Quarter of Fiscal 2015 23Hologic Announces Financial Results for Third Quarter of Fiscal 2015 24Hologic Announces Financial Results for Third Quarter of Fiscal 2015 25WuXi PharmaTech Schedules Second-Quarter 2015 Earnings Release 2Neurocrine Biosciences Reports Second Quarter 2015 Results 2Neurocrine Biosciences Reports Second Quarter 2015 Results 3Neurocrine Biosciences Reports Second Quarter 2015 Results 4Neurocrine Biosciences Reports Second Quarter 2015 Results 5Neurocrine Biosciences Reports Second Quarter 2015 Results 6Neurocrine Biosciences Reports Second Quarter 2015 Results 7Neurocrine Biosciences Reports Second Quarter 2015 Results 8Neurocrine Biosciences Reports Second Quarter 2015 Results 9
... Sept. 22, 2011 Biodel Inc. (Nasdaq: BIOD ... Chief Executive Officer, will be presenting at the 6th Annual ... New York.  The presentation is scheduled for Tuesday, September 27, ... to the live webcast or a replay of the presentation, ...
... Sept. 22, 2011 Reportlinker.com announces that ... in its catalogue: Generic ... http://www.reportlinker.com/p0619265/Generic-Drugs-The-Global-Market--Focus-on-Europe.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment ... * An examination of the strategies employed ...
Cached Medicine Technology:Generic Drugs: The Global Market--Focus on Europe 2Generic Drugs: The Global Market--Focus on Europe 3Generic Drugs: The Global Market--Focus on Europe 4Generic Drugs: The Global Market--Focus on Europe 5Generic Drugs: The Global Market--Focus on Europe 6Generic Drugs: The Global Market--Focus on Europe 7Generic Drugs: The Global Market--Focus on Europe 8Generic Drugs: The Global Market--Focus on Europe 9Generic Drugs: The Global Market--Focus on Europe 10
(Date:7/30/2015)... ... July 30, 2015 , ... After conducting a nationwide ... St. John’s Episcopal Hospital in Far Rockaway, N.Y., has hired Gerard (Jerry) Walsh ... more than 25 years of healthcare leadership experience, Walsh is an expert in organizational ...
(Date:7/30/2015)... Beverly Hills, CA (PRWEB) , ... July 30, 2015 , ... ... safety of the Argus II retinal implant, more commonly known as the “bionic eye,” ... II as a safe and viable tool for patients facing or already affected by ...
(Date:7/30/2015)... ... , ... HEALTHCAREfirst , the leading provider of cloud-based software, services and ... a free webinar detailing the 2016 proposed rule from CMS for home health. , ... of Regulatory Affairs for the National Association for Home Care and Hospice (NAHC), and ...
(Date:7/30/2015)... ... July 30, 2015 , ... The renowned ... grants in its history of funding brain aneurysm research. , Each year, ... life’s work toward scientific research directed at early detection, improved treatment modalities, and ...
(Date:7/30/2015)... Orem, UT (PRWEB) , ... July 30, 2015 , ... When trying to gain weight, many people place a lot ... the amount of calories that need to be consumed. However, another key component to successful ... to gain weight. To assist with this, CB-1 Weight Gainer gives three tips on ...
Breaking Medicine News(10 mins):Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 2Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 4Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 2Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 3
... , , MOUNTAIN VIEW, Calif., Sept. 16 ... Hospital CEO, Ken Graham, will provide insight on health care reform at ... 17 at 7:15 a.m. at the Rotary Summit Center. , , ... contribute to the health care reform debate. El Camino Hospital, a non-profit ...
... , REDMOND, Wash., Sept. 16 It,s ... seats in classrooms and lecture halls because of unfortunate outbreaks of ... to the U.S. Department of Education and schools and universities across ... educators stay connected with their students and continue the learning process ...
... , www.intelligenthospitals.com , , WINNIPEG, Sept. ... of pharmacy across North America, 77% of those looking ... (Robotic Intravenous Automation) - a self-contained unit for filling ... Systems) - as a vendor under consideration. The survey ...
... , , WASHINGTON, Sept. 16 ... CEO of the American Legacy Foundation: , , The ... U.S. House of Representatives who have worked tirelessly to protect Capitol Hill ... , On Thursday, the House,s last two indoor smoking ...
... , NEW YORK, Sept. 16 HMS today announced ... of Human Services (DHS) to provide additional third-party liability services. With ... to 39 state Medicaid agencies. , , "Under ... Billi Jo Zielinski, Assistant Commissioner of Health Care. "This will help ...
... , WASHINGTON, Sept. 16 The U.S. Food and ... a boxed warning regarding the injectable form of the drug. The ... the risk of serious tissue injury when this drug is administered ... new boxed warning for this product, which is used as a ...
Cached Medicine News:Health News:El Camino Hospital Provides Local Perspective on Health Care Reform and Innovation at Silicon Valley Healthcare CEO Summit 2Health News:Microsoft Gives Teachers Free Resources to Address Classroom Challenges Due to the Impact of H1N1 Flu Virus 2Health News:Microsoft Gives Teachers Free Resources to Address Classroom Challenges Due to the Impact of H1N1 Flu Virus 3Health News:IH Systems RIVA Top Pick for Directors of Pharmacy 2Health News:Congress Breathes Easier, Thanks to Speaker Pelosi's Successful Efforts to Eliminate House Smoking Rooms 2Health News:FDA Requires Boxed Warning for Promethazine Hydrochloride Injection 2